2021 World Conference on Lung Cancer (Posters)-FP11. Sustaining and Accelerating Research in Rare Oncogene-Driven Lung Cancers: Lessons From The 2020 ROS1der Research Roundtable

FP11. Sustaining and Accelerating Research in Rare Oncogene-Driven Lung Cancers: Lessons From The 2020 ROS1der Research Roundtable

Back to course

Video Transcription

Video Summary

Janet Freeman Daly, a lung cancer patient and co-founder of the ROS Wonders, provides a summary of the virtual research roundtable they hosted. The roundtable aimed to define barriers, discuss ways to sustain and accelerate ROS1 research, and identify projects for the ROS Wonders to participate in. The main barriers found were the small patient population, lack of data on patient treatment experience, clinical issues, and difficulty acquiring major grants. Opportunities for accelerating and sustaining ROS1 research include promoting universal testing, expanding access to specimens and study results, leveraging real-world data, and studying novel mechanisms of resistance. The ROS Wonders plan to address these findings through current and new projects, expanding their network, and developing standardized frameworks for rare oncogene-driven cancers.

Asset Subtitle

Janet Freeman-Daily

Meta Tag

Speaker Janet Freeman-Daily

Topic Patient Advocacy

Keywords

lung cancer

ROS Wonders

virtual research roundtable

barriers

ROS1 research